ArticleJACC. Asia2022

Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed.

Dao Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.